Cytosorbents Corp
Cytosorbents Corp is listed today as Cytosorbents Corporation: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2013 | $1 M | Private placement after listing | Under $2 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Cytosorbents Corporation, its revenue in fiscal 2025 came from these business segments: Single reportable segment $37.06 million (100%).
Annual report (SEC XBRL) · Dec 2025
Cytosorbents Corp had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Aug 2013).
SEC Form D (revenue range) · Aug 2013
The industry group it chose in its notices: Other Health Care.
SEC Form D · Aug 2013
Products and services#
No products or services of Cytosorbents Corp are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Njtc Investment Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Cytosorbents Corporation shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$0 M0.15%
- CM Management, LLC$0 M0.12%
- Neuberger Berman Group LLC$0 M0.09%
- Skylands Capital, LLC$0 M0.06%
- BlackRock, Inc.$0 M0.05%
- Geode Capital Management, LLC$0 M0.05%
- Pathstone Holdings, LLC$0 M0.04%
- Sargent Investment Group, LLC$0 M0.04%
- Vanguard Fiduciary Trust Co$0 M0.03%
- UBS Group AG$0 M0.01%
- Osaic Holdings, Inc.$0 M0.01%
- Morgan Stanley$0 M0.01%
- Tower Research Capital LLC (TRC)$0 M0.00%
- Nuveen, LLC$0 M0.00%
- Vanguard Global Advisers, LLC$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kathleen P. Bloch | Executive officer | Aug 2013 |
| Phillip Chan | President, Chief Executive Officer and Director | Aug 2013 |
| Vincent P. Capponi | Chief Financial Officer | Aug 2013 |
| Al P. Kraus | Director | Aug 2013 |
| Edward P. Jones | Director | Aug 2013 |
| James P. Gunton | Director | Aug 2013 |
| Joseph P. Rubin | Director | Aug 2013 |
| Phillip Chan | President, Chief Executive Officer and Director | Aug 2013 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.